Difference between revisions of "Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5 (Q9904)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154) |
(Created claim: Page(s) (P105): 929-935, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Sullivan RJ | ||||||||||||||
| Property / First Author string: Sullivan RJ / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1038/s41591-019-0474-7 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 31171876 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2019
| ||||||||||||||
| Property / Publication Date: 2019 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Nat. Med. | ||||||||||||||
| Property / Published In Name String: Nat. Med. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 25 | ||||||||||||||
| Property / Volume: 25 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English) | ||||||||||||||
| Property / title: Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 929-935 | ||||||||||||||
| Property / Page(s): 929-935 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sullivan RJ
0 references
2019
0 references
Nat. Med.
0 references
25
0 references
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English)
0 references
929-935
0 references
